Mechanisms of pulmonary fibrosis
VJ Thannickal, GB Toews, ES White… - Annu. Rev …, 2004 - annualreviews.org
Tissue injury evokes highly conserved, tightly regulated inflammatory responses and less
well-understood host repair responses. Both inflammation and repair involve the …
well-understood host repair responses. Both inflammation and repair involve the …
Side effects of cytokines approved for therapy
BA Baldo - Drug safety, 2014 - Springer
Cytokines, currently known to be more than 130 in number, are small MW (< 30 kDa) key
signaling proteins that modulate cellular activities in immunity, infection, inflammation and …
signaling proteins that modulate cellular activities in immunity, infection, inflammation and …
Role of galectin-3 in human pulmonary fibrosis
Y Nishi, H Sano, T Kawashima, T Okada, T Kuroda… - Allergology …, 2007 - Elsevier
Background: Galectin-β is a p-galactoside-binding protein which is implicated in diverse
physiological and pathological processes including human liver cirrhosis and a mouse lung …
physiological and pathological processes including human liver cirrhosis and a mouse lung …
Interferon-γ protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-β1 …
DL Fairweather, S Frisancho-Kiss, SA Yusung… - The American journal of …, 2004 - Elsevier
Inflammatory fibrosis is a characteristic feature of myocarditis, dilated cardiomyopathy
(DCM), and congestive heart failure. Th1-type immune responses, mediated by interleukin …
(DCM), and congestive heart failure. Th1-type immune responses, mediated by interleukin …
Non‐steroid agents for idiopathic pulmonary fibrosis
P Spagnolo, C Del Giovane, F Luppi… - Cochrane Database …, 1996 - cochranelibrary.com
Abstract Background Idiopathic Pulmonary Fibrosis (IPF) or Usual Interstitial Pneumonia
(UIP) is a form of chronic fibrosing interstitial pneumonia of unknown aetiology, with …
(UIP) is a form of chronic fibrosing interstitial pneumonia of unknown aetiology, with …
Chemotherapy-induced lung disease
AH Limper - Clinics in chest medicine, 2004 - chestmed.theclinics.com
Chemotherapeutic agents are used extensively in solid and hematologic malignancies and
are increasingly used for their immunosuppressive properties in the management of …
are increasingly used for their immunosuppressive properties in the management of …
Current perspectives on the treatment of idiopathic pulmonary fibrosis
N Walter, HR Collard, TE King Jr - Proceedings of the American …, 2006 - atsjournals.org
The clinical course of idiopathic pulmonary fibrosis (IPF) is variable; however, the long-term
survival in IPF is poor. Prednisone has been the mainstay of therapy since its release for …
survival in IPF is poor. Prednisone has been the mainstay of therapy since its release for …
Acute exacerbation of idiopathic pulmonary fibrosis
R Hyzy, S Huang, J Myers, K Flaherty, F Martinez - Chest, 2007 - Elsevier
Background The clinical course of patients with idiopathic pulmonary fibrosis (IPF) is
generally marked by a decline in pulmonary function over time. Increasingly, patients have …
generally marked by a decline in pulmonary function over time. Increasingly, patients have …
Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a clinical entity defined by
rapid deterioration of IPF during the course of the disease that is not due to infections …
rapid deterioration of IPF during the course of the disease that is not due to infections …